Joaquín Martínez Head of Clinical Research Unit
T +34 (+34) 917 328 000 (Ext )
jmartinezl@ext.cnio.es

The Haematological Malignancies Laboratory focuses on investigating novel drivers, biomarkers, diagnostic tools and therapeutic targets and approaches in haematological neoplasms such as myeloma and acute myeloid leukaemia.

Five main lines define our research project:

• Generation of mouse models focused on the molecule hnRNP K, a novel driver of lymphoma and leukaemia.
• Development of novel diagnostic and follow-up tools, such as minimal residual disease analysis in acute myeloid leukaemia (AML).
• Screening of novel drivers, biomarkers and therapeutic targets by next-generation-sequencing (NGS, e.g. exome sequencing of amyloidosis).
• Innovation of immunotherapy approaches. Generation of NK CARs and in vitro/in vivo validation.
• Novel therapeutic approaches. Screening of novel compounds (e.g. hnRNP K inhibitors) and pre-clinical trials of new drugs or drug combinations.

Publications

• Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter ZR, Anderson KC, Treon SP, Munshi NC, Fulciniti M (2019). Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom Macroglobulinemia. Clin Cancer Res 25, 369-377.
• Barrio S, Stühmer T, Da-Viá M, Barrio-Garcia C, Lehners N, Besse A, Cuenca I, Garitano-Trojaola A, Fink S, Leich E, Chatterjee M, Driessen C, Martinez-Lopez J, Rosenwald A, Beckmann R, Bargou RC, Braggio E, Stewart AK, Raab MS, Einsele H, Kortüm KM (2019). Spectrum and functional validation of PSMB5 mutations in multiple myeloma. Leukemia 33, 447-456.
• Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, Pratcorona M, Perez Oteyza J, Herrera P, Barragan E, Montesinos P, Garcia Vela JA, Magro E, Anguita E, Figuera A, Riaza R, Martinez-Barranco P, Sanchez-Vega B, Nomdedeu J, Gallardo M, Martinez-Lopez J, Ayala R (2019). Novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia.. Haematologica 104, 288-296.
• Onecha E, Linares M, Rapado I, Ruiz-Heredia Y, Martinez-Sanchez P, Cedena T, Pratcorona M, Oteyza JP, Herrera P, Barragan E, Montesinos P, Vela JAG, Magro E, Anguita E, Figuera A, Riaza R, Martinez-Barranco P, Sanchez-Vega B, Nomdedeu J, Gallardo M, Martinez-Lopez J, Ayala R (2019). A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia. Haematologica 104, 288-296.
• Alonso CM, Llop M, Sargas C, Pedrola L, Panadero J, Hervás D, Cervera J, Such E, Ibáñez M, Ayala R, Martínez-López J, Onecha E, de Juan I, Palanca S, Martínez-Cuadrón D, Rodríguez-Veiga R, Boluda B, Montesinos P, Sanz G, Sanz MA, Barragán E (2019). Clinical Utility of a Next-Generation Sequencing Panel for Acute Myeloid Leukemia Diagnostics. J Mol Diagn 21, 228-240.
• Linares M, Postigo M, Cuadrado D, Ortiz-Ruiz A, Gil-Casanova S, Vladimirov A, García-Villena J, Nuñez-Escobedo JM, Martínez-López J, Rubio JM, Ledesma-Carbayo MJ, Santos A, Bassat Q, Luengo-Oroz M (2019). Collaborative intelligence and gamification for on-line malaria species differentiation. Malaria J 18, 21.
• Campa D, Martino A, Macauda A, Dudzinski M, Suska A, Druzd-Sitek A, Raab MS, Moreno V, Huhn S, Butrym A, Sainz J, Szombath G, Rymko M, Marques H, Lesueur F, Vangsted AJ, Vogel U, Kruszewski M, Subocz E, Buda G, Iskierka-Jazdzewska E, Ríos R, Merz M, Schöttker B, Mazur G, Perrial E, Martinez-Lopez J, Butterbach K, García Sanz R, Goldschmidt H, Brenner H, Jamroziak K, Reis RM, Kadar K, Dumontet C, Watek M, Haastrup EK, Helbig G, Jurczyszyn A, Jerez A, Varkonyi J, Barington T, Grzasko N, Zaucha JM, Andersen V, Zawirska D, Canzian F (2019). Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study. Leuk Lymphoma (in press).
• Pertesi M, Vallée M, Wei X, Revuelta MV, Galia P, Demangel D, Oliver J, Foll M, Chen S, Perrial E, Garderet L, Corre J, Leleu X, Boyle EM, Decaux O, Rodon P, Kolb B, Slama B, Mineur P, Voog E, Le Bris C, Fontan J, Maigre M, Beaumont M, Azais I, Sobol H, Vignon M, Royer B, Perrot A, Fuzibet JG, Dorvaux V, Anglaret B, Cony-Makhoul P, Berthou C, Desquesnes F, Pegourie B, Leyvraz S, Mosser L, Frenkiel N, Augeul-Meunier K, Leduc I, Leyronnas C, Voillat L, Casassus P, Mathiot C, Cheron N, Paubelle E, Moreau P, Bignon YJ, Joly B, Bourquard P, Caillot D, Naman H, Rigaudeau S, Marit G, Macro M, Lambrecht I, Cliquennois M, Vincent L, Helias P, Avet-Loiseau H, Moreno V, Reis RM, Varkonyi J, Kruszewski M, Vangsted AJ, Jurczyszyn A, Zaucha JM, Sainz J, Krawczyk-Kulis M, Watek M, Pelosini M, Iskierka-Jazdzewska E, Grzasko N, Martinez-Lopez J, Jerez A, Campa D, Buda G, Lesueur F, Dudzinski M, García-Sanz R, Nagler A, Rymko M, Jamroziak K, Butrym A, Canzian F, Obazee O, Nilsson B, Klein RJ, Lipkin SM, McKay JD, Dumontet C (2019). Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia (in press).
• Gallardo M, Malaney P, Aitken MJL, Zhang X, Link TM, Shah V, Alybayev S, Wu MH, Pageon LR, Ma H, Jacamo R, Yu L, Xu-Monette ZY, Steinman H, Lee HJ, Sarbassov D, Rapado I, Barton MC, Martinez-Lopez J, Bueso-Ramos C, Young KH, Post SM (2019). Uncovering the role of hnRNP K, an RNA-binding protein, in B-cell lymphomas. J Natl Cancer I (in press).
• Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators (2018). Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19, 747-757.
• Misiewicz-Krzeminska I, Corchete LA, Rojas EA, Martínez-López J, García-Sanz R, Oriol A, Bladé J, Lahuerta JJ, Miguel JS, Mateos MV, Gutiérrez NC (2018). A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. Haematologica 103, 880-889.
• Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J (2018). Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing. Haematologica 103, e544-e548.
• Genescà E, Lazarenkov A, Morgades M, Berbis G, Ruíz-Xivillé N, Gómez-Marzo P, Ribera J, Juncà J, González-Pérez A, Mercadal S, Guardia R, Artola MT, Moreno MJ, Martínez-López J, Zamora L, Barba P, Gil C, Tormo M, Cladera A, Novo A, Pratcorona M, Nomdedeu J, González-Campos J, Almeida M, Cervera J, Montesinos P, Batlle M, Vives S, Esteve J, Feliu E, Solé F, Orfao A, Ribera JM (2018). Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J Hematol Oncol 11, 96.
• Vela M, Corral D, Carrasco P, Fernández L, Valentín J, González B, Escudero A, Balas A, de Paz R, Torres J, Leivas A, Martinez-Lopez J, Pérez-Martínez A (2018). Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett 422, 107-117.
• Cedena MT, Rapado I, Santos-Lozano A, Ayala R, Onecha E, Abaigar M, Such E, Ramos F, Cervera J, Díez-Campelo M, Sanz G, Rivas JH, Lucía A, Martínez-López J (2018). Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget 9, 30936.
• Macauda A, Castelli E, Buda G, Pelosini M, Butrym A, Watek M, Kruszewski M, Vangsted AJ, Rymko M, Jamroziak K, Abildgaard N, Haastrup EK, Mazur G, Ríos R, Jurczyszyn A, Zawirska D, Dudzinski M, Razny M, Dutka M, Tomczak W, Suska A, Druzd-Sitek A, Marques H, Petrini M, Markiewicz M, Martinez-Lopez J, Ebbesen LH, Iskierka-Jazdzewska E, Sainz J, Canzian F, Campa D (2018). nherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. Br J Haematol 183, 375-384.
• Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, Linares M, Rapado I, Braggio E, Stewart K, Folgueira MD, Ramos A, Collado L, Ruiz J, Toldos O, Hernandez-Lain A, Martinez-Lopez J (2018). Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: A case report. J Oncol Pharm Pract 25, 998-1002.
• Fernández L, Leivas A, Valentín J, Escudero A, Corral D, de Paz R, Vela M, Bueno D, Rodríguez R, Torres JM, Díaz-Almirón M, López-Collazo E, Martinez-Lopez J, Pérez-Martínez A. (2018). How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment?. Transfusion 58, 1340-1347.
• Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marin C, Cedena MT, Paiva B, Puig N, Mateos MV, Ayala R, Hernández MT, Jimenez C, Rosiñol L, Martínez R, Teruel AI, Gutiérrez N, Martin-Ramos ML, Oriol A, Bargay J, Bladé J, San-Miguel J, Garcia-Sanz R, Lahuerta JJ. (2017). Analytical and clinical validation of a novel in-house deep sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.. Leukemia 31, 1446-1449.
• Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Bandi RL, Amodio N, Xu Y, Szalat RL, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC. (2017). Functional role and therapeutic targeting of p21-activated kinase 4 in multiple mieloma.. Blood 129, 2233-2245.
• Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marin F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martinez C, Albors M, Garcia F, Burgaleta C, Besses C. (2017). Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.. Haematologica 102, 103-109.
• Fernández L, Metais JY, Escudero A, Vela M, Valentín J, Vallcorba I, Leivas A, Torres J, Valeri A, Patiño-García A, Martínez J, Leung W, Pérez-Martínez A (2017). Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.. Clin Cancer Res 23, 5824-5835.
• Jiménez C, Jara-Acevedo M, Corchete LA, Castillo D, Ordóñez GR, Sarasquete ME, Puig N, Martínez-López J, Prieto-Conde MI, García-Álvarez M, Chillón MC, Balanzategui A, Alcoceba M, Oriol A, Rosiñol L, Palomera L, Teruel AI, Lahuerta JJ, Bladé J, Mateos MV, Orfão A, San Miguel JF, González M, Gutiérrez NC, García-Sanz R. (2017). A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.. J Mol Diagn 19, 99-106.
• Ribera J, Zamora L, Morgades M, Mallo M, Solanes N, Batlle M, Vives S, Granada I, Juncà J, Malinverni R, Genescà E, Guàrdia R, Mercadal S, Escoda L, Martinez-Lopez J, Tormo M, Esteve J, Pratcorona M, Martinez-Losada C, Solé F, Feliu E, Ribera JM; Spanish PETHEMA Group; Spanish Society of Hematology. (2017). Copy number profiling of adult relapsed B-cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms.. Gene Chromosome Canc 56, 812-820.
• Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Paji? T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S (2016). Development and evaluation of a secondary reference panel for BCR-ABL1 quantitation on the International Scale.. Leukemia 30, 1844-1852.
• Mateos MV, Martínez-Lopez J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, Bladé J, Lahuerta JJ, San-Miguel J (2016). Sequential versus alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.. Blood 127, 420-425.
• Leivas A, Perez-Martinez A, Blanchard MJ, Martín-Clavero E, Fernández L, Lahuerta JJ, Martinez-Lopez J. (2016). Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma.. Oncoimmunology 5, e1250051.
• Santos-Lozano A, Morales-Gonzalez A, Sanchis-Gomar F, Cristi-Montero C, Fiuza-Luces C, Pareja-Galeano H, Martínez-López J, Garatachea N, Lucia A (2016). Response rate to the treatment of Waldenström macroglobulinemia: A meta-analysis of the results of clinical trials.. Crit Rev Oncol Hematol 105, 118-126.
• Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM (2015). hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.. Cancer Cell 28, 486-499.
• Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzi?ski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Juul Vangsted A, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. (2015). Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.. Nat Communications 6, 7539.
• Martínez-López J, Paiva B, López-Anglada L, Mateos MV, Cedena T, Vidríales MB, Sáez-Gómez MA, Contreras T, Oriol A, Rapado I, Teruel AI, Cordón L, Blanchard MJ, Bengoechea E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao A, Bladé J, San Miguel JF, Lahuerta JJ; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. (2015). Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.. Blood 126, 858-862.
• Mateos MV, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J, Martínez-López J, Echeveste MA, Sarrá J, Ocio E, Ramírez G, Martínez R, Palomera L, Payer A, Iglesias R, De la Rubia J, Alegre A, Chinea AI, Bladé J, Lahuerta JJ, San Miguel JF. (2015). Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial.. Haematologica 100, 1096-1102.
• San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Renner C, Bahlis NJ, Yu X, Teasdale T, Sternas L, Jacques C, Zaki MH, Dimopoulos MA. (2015). Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.. Haematologica 100, 1334-1334.
• Mateos MV, Ocio EM, Paiva B, Rosiñol L, Martínez-López J, Bladé J, Lahuerta JJ, García-Sanz R, San Miguel JF (2015). Treatment for patients with newly diagnosed multiple myeloma in 2015.. Blood Rev 29, 387-403.
• Campa D1, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczyszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, García-Sanz R, Buda G, Gemignani F, Ríos R, Vangsted AJ, Dumontet C, Martínez-López J, Moreno MJ, Stepien A, Watek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo E, Dudzinski M, Weinhold N, Reis RM, Canzian F (2015). Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.. Int J Cancer 136, E351-E358.
• Rios R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, Jerez-Cayuela A, W?tek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J (2015). Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.. Endocr-Relat Cancer 22, 545-559.
• Castro N, Rapado I, Ayala R, Martinez-Lopez J (2015). CALR mutations screening should not be studied in splanchnic vein thrombosis.. Br J Haematol 170, 588-589.
• Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014). Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions.. New Engl J Med 370, 1101-1110.
• Papaemmanuil E1, Rapado I2, Li Y1, Potter NE3, Wedge DC1, Tubio J1, Alexandrov LB1, Van Loo P4, Cooke SL1, Marshall J1, Martincorena I1, Hinton J1, Gundem G1, van Delft FW5, Nik-Zainal S1, Jones DR1, Ramakrishna M1, Titley I3, Stebbings L1, Leroy C1, Menzies A1, Gamble J1, Robinson B1, Mudie L1, Raine K1, O'Meara S1, Teague JW1, Butler AP1, Cazzaniga G6, Biondi A6, Zuna J7, Kempski H8, Muschen M9, Ford AM3, Stratton MR1, Greaves M10, Campbell PJ (2014). RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.. Nat Genet 46, 116-125.
• Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capellá G, den Dunnen JT, du Sart D, Fabre A, Farrell MP, Farrington SM, Frayling IM, Frebourg T, Goldgar DE, Heinen CD, Holinski-Feder E, Kohonen-Corish M, Robinson KL, Leung SY, Martins A, Moller P, Morak M, Nystrom M, Peltomaki P, Pineda M, Qi M, Ramesar R, Rasmussen LJ, Royer-Pokora B, Scott RJ, Sijmons R, Tavtigian SV, Tops CM, Weber T, Wijnen J, Woods MO, Macrae F, Genuardi M; InSiGHT (2014). Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.. Nat Genet 46, 107-115.
• Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, Brunet S, Tormo M, Fernández-Abellán P, Guàrdia R, Bernal MT, Esteve J, Barba P, Moreno MJ, Bermúdez A, Cladera A, Escoda L, García-Boyero R, Del Potro E, Bergua J, Amigo ML, Grande C, Rabuñal MJ, Hernández-Rivas JM, Feliu E (2014). Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.. J Clin Oncol 32, 1595-1604.
• Martinez-Lopez J, Lahuerta JJ, Pepin F, González M, Barrio S, Ayala R, Puig N, Montalban MA, Paiva B, Weng L, Jiménez C, Sopena M, Moorhead M, Cedena T, Rapado I, Mateos MV, Rosiñol L, Oriol A, Blanchard MJ, Martínez R, Bladé J, San Miguel J, Faham M, García-Sanz R (2014). Prognostic value of deep sequencing method for minimal residual disease detection in multiple mieloma.. Blood 123, 3073-3079.
• Mateos MV, Oriol A, Martínez-López J, Teruel AI, López de la Guía A, López J, Bengoechea E, Pérez M, Martínez R, Palomera L, de Arriba F, González Y, Hernández JM, Granell M, Bello JL, Bargay J, Peñalver FJ, Martín-Mateos ML, Paiva B, Montalbán MA, Bladé J, Lahuerta JJ, San-Miguel JF (2014). GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?. Blood 124, 1887-1893.
• Martínez N, Almaraz C, Vaqué JP, Varela I, Derdak S, Beltran S, Mollejo M, Campos-Martin Y, Agueda L, Rinaldi A, Kwee I, Gut M, Blanc J, Oscier D, Strefford JC, Martinez-Lopez J, Salar A, Sole F, Rodriguez-Peralto JL, Diez-Tascón C, García JF, Fraga M, Sebastián E, Alvés J, Menárguez J, González-Carreró J, Casado LF, Bayes M, Bertoni F, Gut I, Piris MA (2014). Whole exome sequencing in splenic marginal 1 zone lymphoma reveals mutations in 2 genes involved in marginal zone differentiation.. Leukemia 28, 1334-1340.
• Menezes J, Acquadro F, Wiseman M, Gómez-López G, Salgado RN, Talavera-Casañas JG, Buño I, Cervera JV, Montes-Moreno S, Hernández-Rivas JM, Ayala R, Calasanz MJ, Larrayoz MJ, Brichs LF, Gonzalez-Vicent M, Pisano DG, Piris MA, Alvarez S, Cigudosa JC (2014). Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm.. Leukemia 28, 823-829.
• Puig N, Sarasquete ME, Balanzategui A, Martínez J, Paiva B, García H, Fumero S, Jiménez C, Alcoceba M, Chillón MC, Sebastián E, Marín L, Montalbán MA, Mateos MV, Oriol A, Palomera L, de la Rubia J, Vidriales MB, Bladé J, Lahuerta JJ, González M, Miguel JF, García-Sanz R (2014). Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.. Leukemia 28, 391-397.
• Hernandez-Boluda JC, Pereira A, Gomez M, Boque C, Ferrer-Marin F, Raya JM, Garcia-Gutierrez V, Kerguelen A, Xicoy B, Barba P, Martínez J, Luño E, Alvarez-Larrán A, Martinez-Lopez J, Arbelo E, Besses C (2014). The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.. Haematologica 99, e55-e57.
• Lippert E, Mansier O, Migeon M, Denys B, Nilsson A, Rosmond C, Lode' L, Ugo V, Lascaux A, Bellosillo B, Martinez-Lopez J, Naguib D, Gachard N, Maroc N, Hermouet S (2014). Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.. Haematologica 99, e98-e101.
• Martino A, Campa D, Jurczyszyn A, Martínez-López J, Moreno MJ, Varkonyi J, Dumontet C, García-Sanz R, Gemignani F, Jamroziak K, Stepiel A, Jacobsen SE, Andersen V, Jurado M, Landi S, Rossi AM, Lesueur F, Marques H, Dudzinski M, Watek M, Moreno V, Orciuolo E, Petrini M, Reis RM, Ríos R, Sainz J, Vogel U, Buda G, Vangsted AJ, Canzian F. (2014). Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations–an extensive replication of the associations from the candidate gene era.. Cancer Epidem Biomar 23, 670-674.